Industry Leader articles are written by executives at biopharma companies, consultancies, research firms, and companies that provide services or products to sponsors. The topics are nonpromotional and focused on industrywide business issues.
The Trojan Horse Of Small Talk
Amy Mahery of EMD Serono talks about how to deal with our hidden biases and assumptions related to diversity, equity, and inclusion.
The Challenges — And Opportunities — Facing The European Biotech Industry
Converting cutting-edge research into viable products remains a challenge for the European biotech sector. Jonathan Hay of Delin Ventures investigates how ambition can translate to reality.
I’ve Learned That Hope Is At The Center Of Innovation
In biotech, results show that every innovative success must subsidize nine expensive failures. Fundamentally, this is an industry of optimists, and we do not give up against overwhelming odds.
Building Scientific Trust Virtually
How do you build, manage, and grow global oncology teams in opposite time zones amidst a pandemic? It’s a question I asked myself as I accepted a new position eight months into the COVID-19 lockdown.
How To Overcome Bottlenecks To Expedite Drug Approvals
For most drug developers, the question remains: How can we accelerate delivering new drugs to patients, while at the same time, ensuring those drugs meet stringent regulatory requirements? Here are some tips that may help.
Virtual Marking: A Flexible Option For Pharmaceuticals
Although virtual marking has been available for nearly a decade, courts have provided little specific guidance. Still, there are some points to keep in mind for virtual marking.
Realizing The Value Of Quantum Computing In Life Sciences
In the life sciences sector, quantum computing holds great potential for transforming data-heavy processes, from accelerating drug discovery to simulating clinical trials, and is one of the key technological areas we predict will impact life sciences for the better.
How To Prepare For The Next Healthcare Crisis That We Don’t See Coming
Given everything that we have learned from the COVID-19 situation, healthcare leaders can implement the following key takeaways to help them successfully weather the next storm that comes our way.
Do Biobanks Need New Strategies?
Precision medicine necessitates precision research, which necessitates getting highly specific biospecimens to researchers on demand, in alignment with their demand. Researchers shouldn’t have to adjust their research to whatever specimens are available; supply needs to fit the research.
Building A Legacy With Complex Assets
For life science executives, deciding how to manage your overall portfolio, including illiquid or complex assets, is an important step in preserving both your financial and philanthropic legacies.
BEYOND THE PRINTED PAGE
Starting A Company … In Another Country1/17/2022
Bernard Coulie, M.D., Ph.D., president and CEO of Pliant Therapeutics, a company developing treatments for fibrotic diseases, discusses challenges associated with building a biopharma startup in another country.
A Lesson In Leadership From Lara Sullivan12/22/2021
Lara Sullivan, M.D., CEO of Pyxis Oncology, shares a story showing the impact had by employees in creating the right corporate culture.
The Path That Brought Lara Sullivan To Biopharma12/20/2021
Lara Sullivan, M.D., to be featured in an upcoming issue of Life Science Leader, discusses the entrepreneurial path the brought her to the CEO role at Pyxis Oncology.
LIFE SCIENCE LEADER BLOGS
The decision by J.P. Morgan to make the 2022 annual healthcare conference fully virtual, inspires reflection on the past and advocacy for the future, in this final blog by Rob Wright, retired chief editor, Life Science Leader.
Three biopharmaceutical executives discuss plans around their company getting back to in-office operations.